Pitavastatin magnesium - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for pitavastatin magnesium and what is the scope of patent protection?
Pitavastatin magnesium
is the generic ingredient in one branded drug marketed by Medicure and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.Pitavastatin magnesium has two patent family members in two countries.
There is one drug master file entry for pitavastatin magnesium. Two suppliers are listed for this compound.
Summary for pitavastatin magnesium
| International Patents: | 2 |
| US Patents: | 1 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Master File Entries: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 3 |
| Patent Applications: | 16 |
| What excipients (inactive ingredients) are in pitavastatin magnesium? | pitavastatin magnesium excipients list |
| DailyMed Link: | pitavastatin magnesium at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for pitavastatin magnesium
Generic Entry Date for pitavastatin magnesium*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for pitavastatin magnesium
| Drug Class | HMG-CoA Reductase Inhibitor |
| Mechanism of Action | Hydroxymethylglutaryl-CoA Reductase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for pitavastatin magnesium
US Patents and Regulatory Information for pitavastatin magnesium
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medicure | ZYPITAMAG | pitavastatin magnesium | TABLET;ORAL | 208379-001 | Jul 14, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Medicure | ZYPITAMAG | pitavastatin magnesium | TABLET;ORAL | 208379-002 | Jul 14, 2017 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Medicure | ZYPITAMAG | pitavastatin magnesium | TABLET;ORAL | 208379-003 | Jul 14, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for pitavastatin magnesium
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 2013516459 | ⤷ Try a Trial | |
| World Intellectual Property Organization (WIPO) | 2011089623 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
